$BAP

Analysts made several rating changes: Wolfe upgraded Paychex (PAYX) citing stable employment trends. UBS upgraded Union Pacific (UNP) to Buy with a $339 price target, expecting strong 2027 volume growth. Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target after FDA reaffirmed study design. JPMorgan upgraded Credicorp (BAP) to Overweight with a $482 target, seeing strong EPS growth. Morgan Stanley downgraded Expedia (EXPE) to Underweight with a $235 target, citing weaker assets

Wall Street analysts upgraded Credicorp (BAP) to Overweight, Paychex (PAYX) to Peer Perform, Rocket Pharmaceuticals (RCKT) to Buy, Similarweb (SMWB) to Buy, and Union Pacific (UNP) to Buy. Downgrades include Expedia (EXPE) to Underweight, Grupo Aval (AVAL) to Underweight, Hartford Financial (HIG) to Neutral, Meritage Homes (MTH) to Hold, and Nubank (NU) to Market Perform. Initiations: Airbnb (ABNB) with Equal Weight, Booking Holdings (BKNG) with Overweight, Dutch Bros (BROS) with Buy, Five9 (FIV

Banco de Crédito del Perú (BCP) upgraded its Miami office to a full bank branch, allowing it to serve U.S. companies. The change, effective in July 2026, enables the branch to accept wholesale deposits. BCP, Peru's largest bank, is 97.74% owned by Credicorp (BAP), listed on the NYSE. The branch targets corporate clients, with a goal of 100 new clients by 2027. BCP also plans to acquire Helm Bank USA, pending regulatory approval.

Credicorp (NYSE:BAP) discussed Q2 results and outlook on an earnings call, including plans to reassess El Niño-related expected losses by late Q3 or early Q4. Management said full-year 2026 cost of risk should stay within guidance, raised 2026 loan-growth to ~12% and fee-income to high-teens, and reaffirmed 2026 ROE guidance ~19.5%. BCP ROE 29.2%, Mibanco ROE 22.9%, Yape has 16M+ MAUs.

Analysts covering Credicorp Ltd. raised the consensus 12-month price target to $437.02 from $433.39, based on 13 estimates. Targets range from $376.15 to $480.13. Using the Aug. 13 closing price, the update implies about 16% upside. The consensus rating remains “Buy” with 10 Buys, 3 Holds, and 0 Sells.

Bank of America raised its price target on Credicorp (BAP) to $408 from $361 and kept a Buy rating, citing a rollover of its valuation basis to 2027 and continued bullishness on Peru banks. Credicorp reported fiscal Q1 2026 net income of S/2,063 million (+16.1% YoY, +30.0% QoQ), with ROE at 21.1%, loan growth and improved asset quality.

Markets were mixed ahead of today’s FOMC decision, with traders pricing about a 5% chance of a 25 bp rate hike. US 10-year yields rose to 4.434% after May retail sales and pending home sales beat expectations. Overseas stocks were higher. In Europe, German and UK yields fell; Eurozone core CPI was revised up to 2.6% y/y.

Markets are pricing a 5% chance of a 25 bp rate hike after the FOMC meeting. US May retail sales beat expectations, pushing 10-year yields up to 4.436% while European bund and gilt yields fell. Eurozone May core CPI was revised to 2.6% y/y. Chip stocks rose (AMAT +9%); telecoms fell (Charter -3%). Jabil reported Q3 net revenue $8.80B and raised FY forecast to $35B.

Wall Street analysts issued a range of calls on Wednesday. Bernstein initiated GE Vernova (outperform), NeoVolta (buy, $8 PT) and reiterated Nvidia (outperform). Deutsche Bank raised Micron’s PT to $1,500 ahead of next week’s earnings. Bernstein also lifted AMD to $600, Intel to $100, and Arm to $500. Morgan Stanley downgraded ResMed to equal weight; Citi initiated Figma (buy, $36 PT).

Cavero Diego Antonio (CEO Head Universal Banking) sold 3,500 shares of CREDICORP LTD (BAP) at $319.00 ($1.12M total) on 2026-06-05.